Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minBullish
Daily trend turns down below $7.70
Key levels
Resistance$14.47
Resistance$13.32
Support$10.69
Support$9.71
Latest news & SEC filings
LegalSight Sciences gets CMS rate set for TearCare SmartLids supply code
AnalystPiper Sandler keeps Overweight on Sight Sciences, lifts price target
AnalystPiper Sandler keeps Overweight on Sight Sciences, lifts target to $12
All SGHT news →Sight Sciences makes interventional devices for eye care. Its glaucoma business sells the OMNI Surgical System and the SION Surgical Instrument, which ophthalmic surgeons use in microinvasive glaucoma procedures for adults who have open-angle glaucoma. Its dry eye business sells the TearCare system, which eyecare professionals use to treat meibomian gland dysfunction in adults with evaporative dry eye. The company sells directly in the United States, United Kingdom, and Germany, and through distributors in other parts of Europe.
Based on the company's 10-K filed Mar 4, 2026.
Nasdaq · Healthcare
SEPT Low Target
$6.00
SEPT Mid Target
$11.00
SEPT High Target
$14.00
Analyst Consensus
$11.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SGHT.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$8.88
31
Moat Score
NONE
5/9
Piotroski Score
1.6
Altman Z-Score
Insider Signal
SELLING
1 buys / 13 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Taylor Brenton | officer | Sale | 2,988 | $26K | Oct 2, 2026 |
| Bauerlein Alison | officer | Sale | 25,260 | $224K | Oct 2, 2026 |
| Rodberg James | officer | Sale | 7,208 | $64K | Oct 2, 2026 |
| Badawi David | director officer | Sale | 7,797 | $71K | Oct 1, 2026 |
| Badawi Paul | director officer 10% owner | Sale | 29,653 | $268K | Oct 1, 2026 |
| Encrantz Staffan | director 10% owner | Buy | 14,100 | $69K | Jun 10, 2026 |
| Fountain Tamara | director | Buy | 28,261 | - | Jun 4, 2026 |
| Encrantz Staffan | director 10% owner | Buy | 28,261 | - | Jun 4, 2026 |
| Burbach Gerhard F | director | Buy | 28,261 | - | Jun 4, 2026 |
| Zurbay Donald | director | Buy | 28,261 | - | Jun 4, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-3.1%
3yr Revenue CAGR
2.7%
EPS Growth YoY
28.16%
FCF Growth YoY
-31.6%
Revenue Trend
SLOWING
SEPT Investing tracks real-time dark pool institutional trades for SGHT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:31:49 | $10.89 | 2,800 | $$31K | MIDPOINT |
| 14:31:49 | $10.89 | 2,800 | $$31K | SELL |
| 14:31:49 | $11.00 | 12,436 | $$137K | SELL |
| 21:00:16 | $10.92 | 2,400 | $$26K | BUY |
| 20:36:49 | $10.77 | 5,000 | $$54K | SELL |
5 dark pool trades shown · $$278K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Sight Sciences, Inc. (SGHT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Sight Sciences, Inc. (SGHT) is at $10.85, down 0.64% (-$0.07) at the Nov 12, 2026 close.
Latest SGHT news — Nov 7, 2026: Sight Sciences gets CMS rate set for TearCare SmartLids supply code · Nov 5, 2026: Piper Sandler keeps Overweight on Sight Sciences, lifts price target
The average analyst price target for SGHT is $11.00, ranging from $6 to $14, based on 4 analysts. Latest: Sight Sciences upgrade on Oct 15, 2026.
Analyst ratings for SGHT: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
SGHT last reported on Aug 5, 2026: EPS -$0.08 vs -$0.18 expected — a beat of 56.4%.
SGHT does not currently pay a dividend.
Support: $10.69, $9.71, $9.04. Resistance: $13.32, $14.47.
Insider activity: SELLING, 1 buys and 13 sells in the last 90 days.
Nov 7, 2026: Sight Sciences gets CMS rate set for TearCare SmartLids supply code · Nov 5, 2026: Piper Sandler keeps Overweight on Sight Sciences, lifts price target · Nov 5, 2026: Piper Sandler keeps Overweight on Sight Sciences, lifts target to $12